VBCG
HRTX icon

Valley Brook Capital Group’s Heron Therapeutics HRTX Stock Holding History

Valley Brook Capital Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,300
Closed -$21K – 240
2021
Q1 		$21K Hold
1,300
– – 0.02% 304
2020
Q4 		$27K Buy
+1,300
New +$22.6K 0.03% 254

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Valley Brook Capital Group's HRTX Position: Q2 2021 in Review

Valley Brook Capital Group sold out of Heron Therapeutics (HRTX) in Q2 2021, closing a stake of 1,300 shares — an estimated $21K sold.

Valley Brook Capital Group first reported a position in HRTX in Q4 2020 and held it in 2 quarters. The position peaked at $27K in Q4 2020. 189 funds tracked by Wall St. Rank hold HRTX as of Q2 2021.

  • Valley Brook Capital Group reported no remaining Heron Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Valley Brook Capital Group sold 1,300 Heron Therapeutics shares in Q2 2021, an estimated $21K.
  • Valley Brook Capital Group first reported a position in Heron Therapeutics in Q4 2020 and held it in 2 quarters.
  • Valley Brook Capital Group's Heron Therapeutics position peaked at $27K in Q4 2020.
  • 189 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2021.

Based on Valley Brook Capital Group's 13F filing for Q2 2021, filed 22 Jul 2021.